To provide a review of the status of biomarkers in cystic fibrosis drug development, including regulatory definitions and considerations, a summary of biomarkers in current use with supportive data, current gaps, and future needs
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
BACKGROUND: Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well charac...
Cystic Fibrosis (CF) lung disease is characterized by high levels of cytokines and chemokines in the...
To provide a review of the status of biomarkers in cystic fibrosis drug development, including regul...
Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians, affects approx...
textabstractIn patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (C...
Cystic Fibrosis (CF) is a hereditary, systemic disease caused by mutations in the Cystic Fibrosis Tr...
Sputum biomarkers hold promise as a direct measure of inflammation within the cystic fibrosis (CF) l...
The first regulatory approval for a drug developed specifically for cystic fibrosis (CF) occurred in...
Cystic fibrosis (CF) is a life-shortening disease with significant morbidity. Despite overall improv...
In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) biomark...
Cystic fibrosis is characterized by an overly exuberant neutrophilic inflammatory response to pathog...
Background: Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well charac...
Cystic fibrosis (CF) is the most common life-shortening rare disease caused by mutations in the cyst...
AbstractBackgroundFor cystic fibrosis (CF) patients there is a lack of good assays of disease activi...
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
BACKGROUND: Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well charac...
Cystic Fibrosis (CF) lung disease is characterized by high levels of cytokines and chemokines in the...
To provide a review of the status of biomarkers in cystic fibrosis drug development, including regul...
Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians, affects approx...
textabstractIn patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (C...
Cystic Fibrosis (CF) is a hereditary, systemic disease caused by mutations in the Cystic Fibrosis Tr...
Sputum biomarkers hold promise as a direct measure of inflammation within the cystic fibrosis (CF) l...
The first regulatory approval for a drug developed specifically for cystic fibrosis (CF) occurred in...
Cystic fibrosis (CF) is a life-shortening disease with significant morbidity. Despite overall improv...
In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) biomark...
Cystic fibrosis is characterized by an overly exuberant neutrophilic inflammatory response to pathog...
Background: Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well charac...
Cystic fibrosis (CF) is the most common life-shortening rare disease caused by mutations in the cyst...
AbstractBackgroundFor cystic fibrosis (CF) patients there is a lack of good assays of disease activi...
Chronic respiratory infection is the primary driver of mortality in individuals with cystic fibrosis...
BACKGROUND: Clinical trials in cystic fibrosis (CF) have been hindered by the paucity of well charac...
Cystic Fibrosis (CF) lung disease is characterized by high levels of cytokines and chemokines in the...
DOI
Add to ORKG